Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Improvement in Polycystic Ovarian Syndrome using Pharmacological and Non- Pharmacological Approaches: Current Perspectives and Principles

Author(s): Leander Corrie*, Sachin Kumar Singh, Monica Gulati, Ankit Awasthi, Rubiya Khursheed, Jaskiran Kaur and Sukriti Vishwas

Volume 19, Issue 1, 2023

Published on: 10 May, 2022

Article ID: e290322202754 Pages: 8

DOI: 10.2174/1573404818666220329123334

Price: $65

Abstract

Polycystic ovarian syndrome (PCOS) is characterized by a wide range of metabolic and endocrine abnormalities, which can be quite complex in the diagnosis and treatment. The pathogenesis of PCOS is unclear. Therefore, symptoms of this condition differ from person to person, and it becomes difficult to treat PCOS. So far, many pharmacological interventions such as antilipidemic, ovulatory stimulants, and oral contraceptives have been used alone or in combination for the treatment of PCOS and have not been significantly effective. Precision medicine could be of importance in the treatment of PCOS, and the use of artificial intelligence could be beneficial in understanding the pathogenesis and management of this condition. Biotechnological interventions using small mRNA have been explored for this condition. Moreover, it is also hypothesized that the gut microbiota has a key role in regulating hormones through the gut-brain axis. Herbal remedies have also been used, but it is limited due to improper standardization. The treatment of PCOS is based on providing symptomatic relief and limiting the perpetuation of this condition. Understanding the use of different interventions is important to bring out better clinical outcomes.

Keywords: Polycystic ovarian syndrome, gut microbiota, lifestyle changes, pharmacological interventions, hyperandrogenism, hyperinsulinemia.

Graphical Abstract

[1]
Lujan, M.E.; Chizen, D.R.; Pierson, R.A. Diagnostic criteria for polycystic ovary syndrome: Pitfalls and controversies. J. Obstet. Gynaecol. Can., 2008, 30(8), 671-679.
[http://dx.doi.org/10.1016/S1701-2163(16)32915-2] [PMID: 18786289]
[2]
Rosenfield, R.L.; Ehrmann, D.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev., 2016, 37(5), 467-520.
[http://dx.doi.org/10.1210/er.2015-1104] [PMID: 27459230]
[3]
Roe, A.H.; Dokras, A. The diagnosis of polycystic ovary syndrome in adolescents. Rev. Obstet. Gynecol., 2011, 4(2), 45-51.
[PMID: 22102927]
[4]
Ndefo, U.A.; Eaton, A.; Green, M.R. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. P & T, 2013, 38(6), 336-338.
[5]
Lanzo, E.; Monge, M.; Trent, M. Diagnosis and management of polycystic ovary syndrome in adolescent girls. Pediatr. Ann., 2015, 44(9), e223-e230.
[http://dx.doi.org/10.3928/00904481-20150910-10] [PMID: 26431241]
[6]
Corrie, L.; Gulati, M.; Singh, S.K.; Kapoor, B.; Khursheed, R.; Awasthi, A.; Vishwas, S.; Chellappan, D.K.; Gupta, G.; Jha, N.K.; Anand, K.; Dua, K. Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. Life Sci., 2021, 280, 119753.
[http://dx.doi.org/10.1016/j.lfs.2021.119753] [PMID: 34171379]
[7]
Dennett, C.C.; Simon, J. The role of polycystic ovary syndrome in reproductive and metabolic health: Overview and approaches for treatment. Diabetes Spectr., 2015, 28(2), 116-120.
[http://dx.doi.org/10.2337/diaspect.28.2.116] [PMID: 25987810]
[8]
Corrie, L.; Gulati, M.; Vishwas, S.; Kapoor, B.; Singh, S.K.; Awasthi, A.; Khursheed, R. Combination therapy of curcumin and fecal microbiota transplant: Potential treatment of polycystic ovarian syndrome. Med. Hypotheses, 2021, 154, 110644.
[http://dx.doi.org/10.1016/j.mehy.2021.110644] [PMID: 34332209]
[9]
Homburg, R. Androgen circle of polycystic ovary syndrome. Hum. Reprod., 2009, 24(7), 1548-1555.
[http://dx.doi.org/10.1093/humrep/dep049] [PMID: 19279033]
[10]
Dadachanji, R.; Shaikh, N.; Mukherjee, S. genetic variants associated with hyperandrogenemia in PCOS pathophysiology. Genet. Res. Int., 2018, 2018, 7624932.
[http://dx.doi.org/10.1155/2018/7624932] [PMID: 29670770]
[11]
Baptiste, C.G.; Battista, M.C.; Trottier, A.; Baillargeon, J.P. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol., 2010, 122(1-3), 42-52.
[http://dx.doi.org/10.1016/j.jsbmb.2009.12.010] [PMID: 20036327]
[12]
Lerchbaum, E.; Schwetz, V.; Rabe, T.; Giuliani, A.; Obermayer-Pietsch, B. Hyperandrogenemia in polycystic ovary syndrome: Exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One, 2014, 9(10), e108263.
[http://dx.doi.org/10.1371/journal.pone.0108263] [PMID: 25310562]
[13]
Dunlop, C.E.; Anderson, R.A. The regulation and assessment of follicular growth. Scand. J. Clin. Lab. Invest. Suppl., 2014, 244(sup244), 13-17.
[http://dx.doi.org/10.3109/00365513.2014.936674] [PMID: 25083887]
[14]
Diamanti-Kandarakis, E.; Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev., 2012, 33(6), 981-1030.
[http://dx.doi.org/10.1210/er.2011-1034] [PMID: 23065822]
[15]
Melo, A.S.; Ferriani, R.A.; Navarro, P.A. Treatment of infertility in women with polycystic ovary syndrome: Approach to clinical practice. Clinics (São Paulo), 2015, 70(11), 765-769.
[http://dx.doi.org/10.6061/clinics/2015(11)09] [PMID: 26602525]
[16]
Rojas, J.; Chávez, M.; Olivar, L.; Rojas, M.; Morillo, J.; Mejías, J.; Calvo, M.; Bermúdez, V. Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int. J. Reprod. Med., 2014, 2014, 719050.
[http://dx.doi.org/10.1155/2014/719050] [PMID: 25763405]
[17]
Chang, R.J. The reproductive phenotype in polycystic ovary syndrome. Nat. Clin. Pract. Endocrinol. Metab., 2007, 3(10), 688-695.
[http://dx.doi.org/10.1038/ncpendmet0637] [PMID: 17893687]
[18]
Oh, S.R.; Choe, S.Y.; Cho, Y.J. Clinical application of serum anti-Müllerian hormone in women. Clin. Exp. Reprod. Med., 2019, 46(2), 50-59.
[http://dx.doi.org/10.5653/cerm.2019.46.2.50] [PMID: 31181872]
[19]
De Leo, V.; la Marca, A.; Petraglia, F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr. Rev., 2003, 24(5), 633-667.
[http://dx.doi.org/10.1210/er.2002-0015] [PMID: 14570747]
[20]
Dantas, W.S.; Gualano, B.; Rocha, M.P.; Barcellos, C.R.; dos Reis Vieira Yance, V.; Marcondes, J.A. Metabolic disturbance in PCOS: Clinical and molecular effects on skeletal muscle tissue. ScientificWorldJournal, 2013, 2013, 178364.
[PMID: 23844380]
[21]
Wawrzkiewicz-Jałowiecka, A.; Kowalczyk, K.; Trybek, P.; Jarosz, T.; Radosz, P.; Setlak, M.; Madej, P. In search of new therapeutics-molecular aspects of the PCOS pathophysiology: Genetics, hormones, metabolism and beyond. Int. J. Mol. Sci., 2020, 21(19), 21.
[http://dx.doi.org/10.3390/ijms21197054] [PMID: 32992734]
[22]
Legro, R.S. Obesity and PCOS: Implications for diagnosis and treatment. Semin. Reprod. Med., 2012, 30(6), 496-506.
[http://dx.doi.org/10.1055/s-0032-1328878] [PMID: 23074008]
[23]
Obesity, S.S.; Syndrome, P.O. Obes. Manag., 2007, 3, 69-73.
[http://dx.doi.org/10.1089/obe.2007.0019] [PMID: 20436797]
[24]
Badawy, A.; Elnashar, A. Treatment options for polycystic ovary syndrome. Int. J. Womens Health, 2011, 3, 25-35.
[http://dx.doi.org/10.2147/IJWH.S11304] [PMID: 21339935]
[25]
Goodman, N.F.; Cobin, R.H.; Futterweit, W.; Glueck, J.S.; Legro, R.S.; Carmina, E. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 2. Endocr. Pract., 2015, 21(12), 1415-1426.
[http://dx.doi.org/10.4158/EP15748.DSCPT2] [PMID: 26642102]
[26]
Celec, P.; Ostatníková, D.; Hodosy, J. On the effects of testosterone on brain behavioral functions. Front. Neurosci., 2015, 9, 12.
[http://dx.doi.org/10.3389/fnins.2015.00012] [PMID: 25741229]
[27]
Martin, K.A.; Anderson, R.R.; Chang, R.J.; Ehrmann, D.A.; Lobo, R.A.; Murad, M.H.; Pugeat, M.M.; Rosenfield, R.L. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 2018, 103(4), 1233-1257.
[http://dx.doi.org/10.1210/jc.2018-00241] [PMID: 29522147]
[28]
Kamboj, M.K.; Bonny, A.E. Polycystic ovary syndrome in adolescence: Diagnostic and therapeutic strategies. Transl. Pediatr., 2017, 6(4), 248-255.
[http://dx.doi.org/10.21037/tp.2017.09.11] [PMID: 29184806]
[29]
Pani, A.; Gironi, I.; Di Vieste, G.; Mion, E.; Bertuzzi, F.; Pintaudi, B. From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: Lifestyle and pharmacological management. Int. J. Endocrinol., 2020, 2020, 6276187.
[http://dx.doi.org/10.1155/2020/6276187] [PMID: 32587614]
[30]
Abdalla, M.A.; Deshmukh, H.; Atkin, S.; Sathyapalan, T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab., 2020, 11, 2042018820938305.
[http://dx.doi.org/10.1177/2042018820938305] [PMID: 32670541]
[31]
Daneshjou, D.; Soleimani Mehranjani, M.; Zadeh Modarres, S.; Shariatzadeh, M.A. Sitagliptin/metformin: A new medical treatment in polycystic ovary syndrome. Trends Endocrinol. Metab., 2020, 31(12), 890-892.
[http://dx.doi.org/10.1016/j.tem.2020.09.002] [PMID: 33059962]
[32]
Cunha, J.P. Metformin (Glucophage) vs. Glipizide (Glucotrol)., 2021.
[33]
Puurunen, J.; Piltonen, T.; Puukka, K.; Ruokonen, A.; Savolainen, M.J.; Bloigu, R.; Morin-Papunen, L.; Tapanainen, J.S. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): A prospective, randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab., 2013, 98(12), 4798-4807.
[http://dx.doi.org/10.1210/jc.2013-2674] [PMID: 24152688]
[34]
Sathyapalan, T.; Atkin, S.L. Evidence for statin therapy in polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab., 2010, 1(1), 15-22.
[http://dx.doi.org/10.1177/2042018810367984] [PMID: 23148145]
[35]
Banaszewska, B.; Pawelczyk, L.; Spaczynski, R.Z.; Duleba, A.J. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J. Clin. Endocrinol. Metab., 2011, 96(11), 3493-3501.
[http://dx.doi.org/10.1210/jc.2011-0501] [PMID: 21865358]
[36]
Carmina, E. Polycystic ovary syndrome: Metabolic consequences and long-term management. Scand. J. Clin. Lab. Invest. Suppl., 2014, 244(sup244), 23-26.
[http://dx.doi.org/10.3109/00365513.2014.936676] [PMID: 25083889]
[37]
Chen, Y.; Clegg, N.J.; Scher, H.I. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol., 2009, 10(10), 981-991.
[http://dx.doi.org/10.1016/S1470-2045(09)70229-3] [PMID: 19796750]
[38]
Harborne, L.; Fleming, R.; Lyall, H.; Sattar, N.; Norman, J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2003, 88(9), 4116-4123.
[http://dx.doi.org/10.1210/jc.2003-030424] [PMID: 12970273]
[39]
Diri, H.; Bayram, F.; Simsek, Y.; Caliskan, Z.; Kocer, D. Comparison of finasteride, metformin, and finasteride plus metformin in PCOS. Acta Endocrinol. (Bucur.), 2017, 13(1), 84-89.
[http://dx.doi.org/10.4183/aeb.2017.84] [PMID: 31149153]
[40]
Ganie, M.A.; Khurana, M.L.; Eunice, M.; Gupta, N.; Gulati, M.; Dwivedi, S.N.; Ammini, A.C. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J. Clin. Endocrinol. Metab., 2004, 89(6), 2756-2762.
[http://dx.doi.org/10.1210/jc.2003-031780] [PMID: 15181054]
[41]
Zasada, M.; Budzisz, E. Retinoids: Active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol. Alergol., 2019, 36(4), 392-397.
[http://dx.doi.org/10.5114/ada.2019.87443] [PMID: 31616211]
[42]
Acmaz, G.; Cınar, L.; Acmaz, B.; Aksoy, H.; Kafadar, Y.T.; Madendag, Y.; Ozdemir, F.; Sahin, E.; Muderris, I. The effects of oral isotretinoin in women with acne and polycystic ovary syndrome. BioMed Res. Int., 2019, 2019, 2513067.
[http://dx.doi.org/10.1155/2019/2513067] [PMID: 31080813]
[43]
Ozdemir, M.; Toy, H.; Mevlitoğlu, I.; Demirkesen, C. Generalized idiopathic acanthosis nigricans treated with acitretin. J. Dermatolog. Treat., 2006, 17(1), 54-56.
[http://dx.doi.org/10.1080/09546630500497280] [PMID: 16511962]
[44]
Wong, R.S.Y. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in cancer prevention and cancer promotion. Adv. Pharmacol. Sci., 2019, 2019, 3418975.
[http://dx.doi.org/10.1155/2019/3418975] [PMID: 30838040]
[45]
Pannunzio, A.; Coluccia, M. Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: A review of oncology and medicinal chemistry literature. Pharmaceuticals (Basel), 2018, 11(4), 11.
[http://dx.doi.org/10.3390/ph11040101] [PMID: 30314310]
[46]
Olaniyan, O.T.; Bamidele, O.; Uche, S.; Femi, A.; Ayobami, D.; Ayoola, O.; Builders, M.; Mali, P.C. Ovarian metabolic activity in dehydroepiandrosterone-induced polycystic ovary in Wistar rats treated with aspirin. JBRA Assist. Reprod., 2020, 24(1), 41-54.
[PMID: 31608617]
[47]
Bagis, T.; Gokcel, A.; Zeyneloglu, H.B.; Tarim, E.; Kilicdag, E.B.; Haydardedeoglu, B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: A prospective randomized study. J. Clin. Endocrinol. Metab., 2002, 87(10), 4536-4540.
[http://dx.doi.org/10.1210/jc.2002-020294] [PMID: 12364431]
[48]
Yauger, B.J.; Gorden, P.; Park, J.; Cochran, E.; Stratton, P. Effect of depot medroxyprogesterone acetate on glucose tolerance in generalized lipodystrophy. Obstet. Gynecol., 2008, 112(2 Pt 2), 445-447.
[http://dx.doi.org/10.1097/AOG.0b013e3181662d17] [PMID: 18669758]
[49]
Bahamondes, L.; Valeria Bahamondes, M.; Shulman, L.P. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum. Reprod. Update, 2015, 21(5), 640-651.
[http://dx.doi.org/10.1093/humupd/dmv023] [PMID: 26037216]
[50]
Chaudhury, A.; Duvoor, C.; Reddy Dendi, V.S.; Kraleti, S.; Chada, A.; Ravilla, R.; Marco, A.; Shekhawat, N.S.; Montales, M.T.; Kuriakose, K.; Sasapu, A.; Beebe, A.; Patil, N.; Musham, C.K.; Lohani, G.P.; Mirza, W. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front. Endocrinol. (Lausanne), 2017, 8, 6.
[http://dx.doi.org/10.3389/fendo.2017.00006] [PMID: 28167928]
[51]
Tauchen, J.; Jurášek, M.; Huml, L.; Rimpelová, S. Medicinal use of testosterone and related steroids revisited. Molecules, 2021, 26(4), 26.
[http://dx.doi.org/10.3390/molecules26041032] [PMID: 33672087]
[52]
Vuong, C.; Van Uum, S.H.; O’Dell, L.E.; Lutfy, K.; Friedman, T.C. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr. Rev., 2010, 31(1), 98-132.
[http://dx.doi.org/10.1210/er.2009-0009] [PMID: 19903933]
[53]
Shadoan, M.K.; Kavanagh, K.; Zhang, L.; Anthony, M.S.; Wagner, J.D. Addition of medroxyprogesterone acetate to conjugated equine estrogens results in insulin resistance in adipose tissue. Metabolism, 2007, 56(6), 830-837.
[http://dx.doi.org/10.1016/j.metabol.2007.01.014] [PMID: 17512317]
[54]
Corremans, R.; Vervaet, B.A.; D’Haese, P.C.; Neven, E.; Verhulst, A. Metformin: A candidate drug for renal diseases. Int. J. Mol. Sci., 2018, 20(1), 20.
[http://dx.doi.org/10.3390/ijms20010042] [PMID: 30583483]
[55]
Froment, P.; Touraine, P. Thiazolidinediones and fertility in Polycystic Ovary Syndrome (PCOS). PPAR Res., 2006, 2006, 73986.
[http://dx.doi.org/10.1155/PPAR/2006/73986] [PMID: 17347533]
[56]
Benelli, E.; Del Ghianda, S.; Di Cosmo, C.; Tonacchera, M. A combined therapy with myo-inositol and D-Chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J. Endocrinol., 2016, 2016, 3204083.
[http://dx.doi.org/10.1155/2016/3204083] [PMID: 27493664]
[57]
Dawson, A.J.; Sathyapalan, T.; Vince, R.; Coady, A.M.; Ajjan, R.A.; Kilpatrick, E.S.; Atkin, S.L. The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome. Front. Endocrinol. (Lausanne), 2019, 10, 189.
[http://dx.doi.org/10.3389/fendo.2019.00189] [PMID: 31001199]
[58]
Charny, J.W.; Choi, J.K.; James, W.D. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int. J. Womens Dermatol., 2017, 3(2), 111-115.
[http://dx.doi.org/10.1016/j.ijwd.2016.12.002] [PMID: 28560306]
[59]
Leo DL, V.D.; Antona, D.D.; Marca, A.L.; Morgante, G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1998, 83, 4500.
[60]
Wu, C.; Jiang, F.; Wei, K.; Lin, F.; Jiang, Z. Effects of exercise combined with finasteride on hormone and ovarian function in polycystic ovary syndrome rats. Int. J. Endocrinol., 2019, 2019, 8405796.
[http://dx.doi.org/10.1155/2019/8405796] [PMID: 31001337]
[61]
Azziz, R.; Black, V.Y.; Knochenhauer, E.S.; Hines, G.A.; Boots, L.R. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J. Clin. Endocrinol. Metab., 1999, 84(3), 946-950.
[PMID: 10084576]
[62]
Takasaki, A.; Tamura, I.; Okada-Hayashi, M.; Orita, T.; Tanabe, M.; Maruyama, S.; Shimamura, K.; Morioka, H. Usefulness of intermittent clomiphene citrate treatment for women with polycystic ovarian syndrome that is resistant to standard clomiphene citrate treatment. Reprod. Med. Biol., 2018, 17(4), 454-458.
[http://dx.doi.org/10.1002/rmb2.12219] [PMID: 30377399]
[63]
Agrawal, N.K. Management of hirsutism. Indian J. Endocrinol. Metab., 2013, 17(7)(Suppl. 1), S77-S82.
[http://dx.doi.org/10.4103/2230-8210.119511] [PMID: 24251227]
[64]
Peña, A.S.; Witchel, S.F.; Hoeger, K.M.; Oberfield, S.E.; Vogiatzi, M.G.; Misso, M.; Garad, R.; Dabadghao, P.; Teede, H. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med., 2020, 18(1), 72.
[http://dx.doi.org/10.1186/s12916-020-01516-x] [PMID: 32204714]
[65]
Banaszewska, B.; Wrotyńska-Barczyńska, J.; Spaczynski, R.Z.; Pawelczyk, L.; Duleba, A.J. Effects of resveratrol on polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab., 2016, 101(11), 4322-4328.
[http://dx.doi.org/10.1210/jc.2016-1858] [PMID: 27754722]
[66]
Arentz, S.; Abbott, J.A.; Smith, C.A.; Bensoussan, A. Herbal medicine for the management of Polycystic Ovary Syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement. Altern. Med., 2014, 14(1), 511.
[http://dx.doi.org/10.1186/1472-6882-14-511] [PMID: 25524718]
[67]
Efird, J.T.; Choi, Y.M.; Davies, S.W.; Mehra, S.; Anderson, E.J.; Katunga, L.A. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int. J. Environ. Res. Public Health, 2014, 11(2), 2328-2345.
[http://dx.doi.org/10.3390/ijerph110202328] [PMID: 24566057]
[68]
Samad Zare, M.N.A.T. The effects of Urtica dioica extract on lipid profile, insulin resistance index and liver histology in polycystic ovary syndrome induced Wistar rats. Adv. Herb. Med., 2015, 1, 23-33.
[69]
Khot, B.M. Clinical efficacy of ayurveda treatment on polycystic ovarian syndrome. IOSR J. Pharm., 2013, 3(4), 21-25.
[http://dx.doi.org/10.9790/3013-0343021-25]
[70]
Swaroop, A.; Jaipuriar, A.S.; Gupta, S.K.; Bagchi, M.; Kumar, P.; Preuss, H.G.; Bagchi, D. Efficacy of a novel fenugreek seed extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS). Int. J. Med. Sci., 2015, 12(10), 825-831.
[http://dx.doi.org/10.7150/ijms.13024] [PMID: 26516311]
[71]
Yang, H.; Lee, S.Y.; Lee, S.R.; Pyun, B.J.; Kim, H.J.; Lee, Y.H.; Kwon, S.W.; Suh, D.H.; Lee, C.H.; Hong, E.J.; Lee, H.W. Therapeutic effect of Ecklonia cava extract in letrozole-induced polycystic ovary syndrome rats. Front. Pharmacol., 2018, 9, 1325.
[http://dx.doi.org/10.3389/fphar.2018.01325] [PMID: 30524282]
[72]
Reddy, P.S.; Begum, N.; Mutha, S.; Bakshi, V. Beneficial effect of Curcumin in Letrozole induced polycystic ovary syndrome. Asian Pac. J. Reprod., 2016, 5(2), 116-122.
[http://dx.doi.org/10.1016/j.apjr.2016.01.006]
[73]
Butler, A.E.; Ramachandran, V.; Sathyapalan, T.; David, R.; Gooderham, N.J.; Benurwar, M.; Dargham, S.R.; Hayat, S.; Hani Najafi-Shoushtari, S.; Atkin, S.L. MicroRNA expression in women with and without polycystic ovarian syndrome matched for body mass index. Front. Endocrinol. (Lausanne), 2020, 11, 206.
[http://dx.doi.org/10.3389/fendo.2020.00206] [PMID: 32411089]
[74]
Colpaert, R.M.W.; Calore, M. MicroRNAs in cardiac diseases. Cells, 2019, 8(7), 8.
[http://dx.doi.org/10.3390/cells8070737] [PMID: 31323768]
[75]
Chen, Z.; Ou, H.; Wu, H.; Wu, P.; Mo, Z. Role of microRNA in the pathogenesis of polycystic ovary syndrome. DNA Cell Biol., 2019, 38(8), 754-762.
[http://dx.doi.org/10.1089/dna.2019.4622] [PMID: 31305133]
[76]
Rizk, M.G.; Thackray, V.G. Intersection of polycystic ovary syndrome and the gut microbiome. J. Endocr. Soc., 2021, 5, bvaa177.
[77]
Zhao, X.; Jiang, Y.; Xi, H.; Chen, L.; Feng, X. Exploration of the relationship between gut microbiota and Polycystic Ovary Syndrome (PCOS): A review. Geburtshilfe Frauenheilkd., 2020, 80(2), 161-171.
[http://dx.doi.org/10.1055/a-1081-2036] [PMID: 32109968]
[78]
Torres, P.J.; Siakowska, M.; Banaszewska, B.; Pawelczyk, L.; Duleba, A.J.; Kelley, S.T.; Thackray, V.G. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J. Clin. Endocrinol. Metab., 2018, 103(4), 1502-1511.
[http://dx.doi.org/10.1210/jc.2017-02153] [PMID: 29370410]
[79]
Matijašić, M.; Meštrović, T.; Paljetak, H.C.; Perić, M.; Barešić, A.; Verbanac, D. Gut microbiota beyond bacteria-mycobiome, virome, archaeome, and eukaryotic parasites in IBD. Int. J. Mol. Sci., 2020, 21(8), 21.
[http://dx.doi.org/10.3390/ijms21082668] [PMID: 32290414]
[80]
Zhang, J.; Sun, Z.; Jiang, S.; Bai, X.; Ma, C.; Peng, Q.; Chen, K.; Chang, H.; Fang, T.; Zhang, H. Probiotic bifidobacterium lactis v9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. mSystems, 2019, 4(2), 4.
[http://dx.doi.org/10.1128/mSystems.00017-19] [PMID: 31020040]
[81]
Quaranta, G.; Sanguinetti, M.; Masucci, L. Fecal microbiota transplantation: A potential tool for treatment of human female reproductive tract diseases. Front. Immunol., 2019, 10, 2653.
[http://dx.doi.org/10.3389/fimmu.2019.02653] [PMID: 31827467]
[82]
Gulati, M.; Singh, S.K.; Corrie, L.; Kaur, I.P.; Chandwani, L. Delivery routes for faecal microbiota transplants: Available, anticipated and aspired. Pharmacol. Res., 2020, 159, 104954.
[http://dx.doi.org/10.1016/j.phrs.2020.104954] [PMID: 32492490]
[83]
de Lima Nunes, R.; Dos Santos, I.K.; Cobucci, R.N.; Pichini, G.S.; Soares, G.M.; de Oliveira Maranhão, T.M.; Dantas, P.M.S. Lifestyle interventions and quality of life for women with polycystic ovary syndrome: A systematic review and meta-analysis protocol. Medicine (Baltimore), 2019, 98(50), e18323.
[http://dx.doi.org/10.1097/MD.0000000000018323] [PMID: 31852122]
[84]
Sedighi, S.; Amir Ali Akbari, S.; Afrakhteh, M.; Esteki, T.; Alavi Majd, H.; Mahmoodi, Z. Comparison of lifestyle in women with polycystic ovary syndrome and healthy women. Glob. J. Health Sci., 2014, 7(1), 228-234.
[http://dx.doi.org/10.5539/gjhs.v7n1p228] [PMID: 25560358]
[85]
Cheng, J.J.; Mahalingaiah, S. Data mining polycystic ovary morphology in electronic medical record ultrasound reports. Fertil. Res. Pract., 2019, 5(1), 13.
[http://dx.doi.org/10.1186/s40738-019-0067-7] [PMID: 31827874]
[86]
Day, F.; Karaderi, T.; Jones, M.R.; Meun, C.; He, C.; Drong, A.; Kraft, P.; Lin, N.; Huang, H.; Broer, L.; Magi, R.; Saxena, R.; Laisk, T.; Urbanek, M.; Hayes, M.G.; Thorleifsson, G.; Fernandez-Tajes, J.; Mahajan, A.; Mullin, B.H.; Stuckey, B.G.A.; Spector, T.D.; Wilson, S.G.; Goodarzi, M.O.; Davis, L.; Obermayer-Pietsch, B.; Uitterlinden, A.G.; Anttila, V.; Neale, B.M.; Jarvelin, M.R.; Fauser, B.; Kowalska, I.; Visser, J.A.; Andersen, M.; Ong, K.; Stener-Victorin, E.; Ehrmann, D.; Legro, R.S.; Salumets, A.; McCarthy, M.I.; Morin-Papunen, L.; Thorsteinsdottir, U.; Stefansson, K.; Styrkarsdottir, U.; Perry, J.R.B.; Dunaif, A.; Laven, J.; Franks, S.; Lindgren, C.M.; Welt, C.K. 23andMe Research Team. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet., 2018, 14(12), e1007813.
[http://dx.doi.org/10.1371/journal.pgen.1007813] [PMID: 30566500]
[87]
Kim, S.Y.; Kim, S.K.; Lee, J.R.; Woodruff, T.K. Toward precision medicine for preserving fertility in cancer patients: Existing and emerging fertility preservation options for women. J. Gynecol. Oncol., 2016, 27(2), e22.
[http://dx.doi.org/10.3802/jgo.2016.27.e22] [PMID: 26768785]
[88]
Xie, N.N.; Wang, F.F.; Zhou, J.; Liu, C.; Qu, F. Establishment and analysis of a combined diagnostic model of polycystic ovary syndrome with random forest and artificial neural network. BioMed Res. Int., 2020, 2020, 2613091.
[http://dx.doi.org/10.1155/2020/2613091] [PMID: 32884937]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy